Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study

Antiviral Therapy

Volumn 10, Issue 1, 2005, Pages 145-155

  Kappelhoff, Bregt S ^a   Van Leth, Frank ^b   MacGregor, Thomas R ^c   Lange, Joep M A ^b   Beijnen, Jos H ^a,d   Huitema, Alwin D R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OXAZINE DERIVATIVE;

ADULT; ARTICLE; BAYES THEOREM; COMORBIDITY; COMPARTMENT MODEL; COVARIANCE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOUTH AFRICA; SOUTH AMERICA; STATISTICAL ANALYSIS; THAILAND; VIRUS INFECTION; ANALYSIS OF VARIANCE; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE;

EID: 18344380712     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M & Lange JMA. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Italy, The Netherlands, Canada and Australia Study. Journal of the American Medical Association 1998; 279:930-937.
2. Lange JMA. Efficacy and durability of nevirapine in anti-retroviral drug naive patients. Journal of Acquired Immune Deficiency Syndromes 2003; 34(Suppl 1):S40-S52.
3. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ & Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. New England Journal of Medicine 1999; 341:1865-1873.
4. Haas DW, Fessel WJ, Delapenha RA, Kessler H, Seekins D, Kaplan M, Ruiz NM, Ploughman LM, Labriola DF & Manion DJ. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. Journal of Infectious Diseases 2001; 183:392-400.
5. Arranz-Caso JA, Gorgolas M, Estrada V & Garcia-Diaz JD. Treatment of HIV-infected patients with a combination of efavirenz, nevirapine and nucleoside reverse transcriptase inhibitors. HIV Medicine 2004; 5:128-129.
6. Jordan WC, Jefferson R, Yemofio F, Tolbert L, Conlon V, Carroll H, Green DC, Green A & Green R. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection. Journal of the National Medical Association 2003; 95:1152-1157.
7. Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, Van Der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW & Lange JMA; 2NN Study Team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
8. Veldkamp AI, Harris M, Montaner JS, Moyle G, Gazzard B, Youle M, Johnson M, Kwakkelstein MO, Carlier H, van Leeuwen R, Beijnen JH, Lange JMA, Reiss P & Hoetelmans RMW. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. Journal of Infectious Diseases 2001; 184:37-42.
9. Lamson M, MacGregor T, Riska P, Erickson D, Maxfield P, Rowland L, Gigliotti M, Robinson P, Azzam S & Keirns J. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. 100th American Society for Clinical Pharmacology & Therapeutics. 18-20 March 1999, San Antonio, TX, USA. Abstract PI-79.
10. Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J & Keirns J. Disposition and biotransformation of the anti-retroviral drug nevirapine in humans. Drug Metabolism & Disposition 1999; 27:895-901.
11. Kappelhoff BS, Rosing H, Huitema ADR & Beijnen JH. Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography. Journal of Chromatography, B: Analytical Technologies in the Biomedical & Life Sciences 2003; 792:353-362.
12. Beal S & Sheiner L. NONMEM User's Guides. NONMEM Project Group. 1998. San Francisco: University of California at San Francisco.
13. De Maat MMR, Huitema ADR, Mulder JW, Meenhorst PL, van Gorp ECM & Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. British Journal of Clinical Pharmacology 2002; 54:378-385.
14. Kappelhoff BS, Huitema ADR, Yalvaç Z, Prins JM, Mulder JW, Meenhorst PL & Beijnen JH. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clinical Pharmacokinetics 2005; in press.
15. Kowalski KG & Hutmacher MM. Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test. Journal of Pharmacokinetics & Pharmacodynamics 2001; 28:253-275.
16. Karlsson MO, Jonsson EN, Wiltse CG & Wade JR. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. Journal of Pharmacokinetics & Biopharmaceutics 1998; 26:207-246.
17. Parke J, Holford NH & Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Computer Methods & Programs in Biomedicine 1999; 59:19-29.
18. Wahlby U, Jonsson EN & Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. Journal of Pharmacokinetics & Pharmacodynamics 2001; 28:231-252.
19. Yano Y, Beal SL & Sheiner LB. Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. Journal of Pharmacokinetics & Pharmacodynamics 2001; 28:171-192.
20. de Maat MMR, Ekhart GC, Huitema ADR, Koks CHW, Mulder JW & Beijnen JH. Drug interactions between anti-retroviral drugs and comedicated agents. Clinical Pharmacokinetics 2003; 42:223-282.
21. Zhou XJ, Sheiner LB, D'Aquila RT, Hughes MD, Hirsch MS, Fischl MA, Johnson VA, Myers M & Sommadossi JP. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrobial Agents & Chemotherapy 1999; 43:121-128.
22. Wade JR, Kelman AW, Howie CA & Whiting B. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. Journal of Pharmacokinetics & Biopharmaceutics 1993; 21:209-222.
23. Pfister M, Labbe L, Hammer SM, Mellors J, Bennett KK, Rosenkranz S & Sheiner LB. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrobial Agents & Chemotherapy 2003; 47:130-137.
24. Csajka C, Marzolini C, Fattinger K, Decosterd LA, Fellay J, Telenti A, Biollaz J & Buclin T. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clinical Pharmacology & Therapeutics 2003; 73:20-30.
25. Smith PF, DiCenzo R & Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clinical Pharmacokinetics 2001; 40:893-905.
26. Meibohm B, Beierle I & Derendorf H. How important are gender differences in pharmacokinetics? Clinical Pharmacokinetics 2002; 41:329-342.
27. Sowunmi A, Rashid TJ, Akinyinka OO & Renwick AG. Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. British Journal of Clinical Pharmacology 1995; 40:489-493.
28. Haas DW, Ribaudo H, Kim R, Tierney C, Wilkinson GR, Gulick R, Clifford D, Hulgan T & Acosta E. A common CYP2B6 variant is associated with efavirenz pharmacokinetics and central nervous system side effects: AACTG study NWCS214. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 133.
29. Kinirons MT, Lang CC, He HB, Ghebreselasie K, Shay S, Robin DW & Wood AJ. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. British Journal of Clinical Pharmacology 1996; 41:69-72.
30. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ & Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clinical Pharmacology & Therapeutics 2000; 68:82-91.
31. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J & Schuetz EG. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12:121-132.